Viral Genetics Inc. is a biotechnology company with a focus on protein-based therapeutic and diagnostic products with applications in infectious disease, autoimmune conditions, and immunological deficiency. The company and its management team are key players in the fight against HIV/AIDS, infectious disease, and autoimmune deficiency. Viral Genetics has been working since 1995 to find a cure for HIV/AIDS and is based in Azusa, California.
VRAL develops its products based on thymus nuclear protein (TNP), a processed extract of mammalian thymus tissue. It has developed a lead product, VGV-1, which is a suspension of TNP in alum adjuvant for the treatment of HIV infection and AIDS. VGV-1 is currently in the preclinical stage of development in the United States, but outside of the USA it is in later stage development. Viral Genetics believes that VGV-1 represents a significant and unique approach to treating HIV due to the apparently novel mechanism, low toxicity profile, simple dosing regimen, and short-course of treatment.
Over the past 13 years, Viral Genetics has performed five human clinical trials in South Africa, China, Bulgaria, and Mexico utilizing VGV-1, and each time the results have suggested a significant decrease in the HIV viral load. The HIV market has historically had high growth rates because of the desperate need for a cure. According to the World Health Organization’s annual report in 2007, the number of people infected with HIV or AIDS globally had reached 33.2 million. With such a desperate need for a cure, companies like Viral Genetics are vital to the global market as the anticipation for a cure to this epidemic grows by the day.
Let us hear your thoughts: Viral Genetics Inc. Message Board